Cantargia publishes half year report
Cantargia AB’s (”Cantargia”) half year report for the period January until June 2021 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.
Significant events in the second quarter
- Preclinical results for the CAN10 antibody were presented at the IMMUNOLOGY2021 conference.
- A letter of intent was signed with GEICAM to conduct a clinical study with nadunolimab in combination with carboplatin/gemcitabine in triple negative breast cancer.
- Positive interim results were presented from the CANFOUR study showing an improved progression-free survival and overall survival for combination treatment with nadunolimab and chemotherapy in pancreatic cancer, compared to historical control data.
- Regulatory approval was obtained to initiate the phase Ib study CAPAFOUR with nadunolimab in combination with the FOLFIRINOX chemotherapy regimen in pancreatic cancer.
- An application was submitted to start the clinical phase Ib/II study CESTAFOUR with nadunolimab in combination with chemotherapy in three different cancers.
Significant events after the end of the period
- An application was submitted to start the clinical phase Ib/II study TRIFOUR with nadunolimab in combination with carboplatin/gemcitabine in triple negative breast cancer.
|First half 2021 (1 Jan 2021 – 30 Jun 2021)|
In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 19, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the period April – June 2021, followed by a Q&A-session.
The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q2-2021.
To attend through telephone, please dial-in at one of the numbers below:
SE: +46 850558369
UK: +44 3333009274
US: +1 6319131422 PIN: 40478324#
The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on August 19, 2021.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
About nadunolimab (CAN04)
The antibody CAN04 binds strongly to the target IL1RAP and functions both through ADCC as well as blocking IL-1α and IL-1β signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in three ongoing clinical trials. In the first phase I/IIa-study, CANFOUR, first line combination therapy is investigated using two different standard chemotherapies in patients with NSCLC (gemcitabine/cisplatin) and patients with PDAC (gemcitabine/nab-paclitaxel), as well as monotherapy in late stage patients (https://clinicaltrials.gov/ct2/show/NCT03267316). Phase I monotherapy data from 22 patients were presented at ASCO 2019 and showed good safety with infusion-related reaction being the most common side effect. In addition, the biomarkers IL-6 and CRP decreased during treatment. Positive interim data from the combination therapies show durable responses or pseudoprogression in patients with PDAC, resulting in iPFS of 7.8 months, and also a higher response rate of patients with NSCLC, compared to chemotherapy alone. A phase I study, CAPAFOUR, was initiated in H1 2021 and will investigate CAN04 in combination with the chemotherapy regimen FOLFIRINOX for first line treatment of metastatic PDAC https://clinicaltrials.gov/ct2/show/NCT04990037. A phase I study, CIRIFOUR, is also currently investigating CAN04 in combination with an immune checkpoint inhibitor and was started H2 2020 (https://clinicaltrials.gov/ct2/show/NCT04452214). Additional clinical combination studies are planned to start during 2021.